On the public citation graph

Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection

0 signed · 53 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cmdc.201300343openalex-snapshot

Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity

inferredcites →https://doi.org/10.1002/hep.27934openalex-snapshot

Hepatitis C virus drug resistance–associated substitutions: State of the art summary

inferredcites →https://doi.org/10.1002/hep.27950openalex-snapshot

Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

inferredcites →https://doi.org/10.1002/hep.29139openalex-snapshot

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

inferredcites →https://doi.org/10.1002/hep.29358openalex-snapshot

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

inferredcites →https://doi.org/10.1002/hep.29837openalex-snapshot

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors

inferredcites →https://doi.org/10.1002/hep4.1050openalex-snapshot

Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review

inferredcites →https://doi.org/10.1002/jmv.25048openalex-snapshot

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies

inferredcites →https://doi.org/10.1007/978-1-62703-484-5_12openalex-snapshot

Amplification and Sequencing of the Hepatitis C Virus NS3/4A Protease and the NS5B Polymerase Regions for Genotypic Resistance Detection of Clinical Isolates of Subtypes 1a and 1b

inferredcites →https://doi.org/10.1016/j.antiviral.2014.10.010openalex-snapshot

Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C

inferredcites →https://doi.org/10.1016/j.jhep.2015.04.009openalex-snapshot

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

inferredcites →https://doi.org/10.1016/s0140-6736(15)00349-9openalex-snapshot

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

inferredcites →https://doi.org/10.1016/s0168-8278(15)30073-8openalex-snapshot

O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir

inferredcites →https://doi.org/10.1016/s2352-3018(15)00114-9openalex-snapshot

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

inferredcites →https://doi.org/10.1053/j.gastro.2016.04.003openalex-snapshot

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

inferredcites →https://doi.org/10.1053/j.gastro.2016.09.045openalex-snapshot

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

inferredcites →https://doi.org/10.1053/j.gastro.2017.12.015openalex-snapshot

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants

inferredcites →https://doi.org/10.1053/j.gastro.2018.02.017openalex-snapshot

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models

inferredcites →https://doi.org/10.1056/nejmoa1613512openalex-snapshot

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

inferredcites →https://doi.org/10.1093/cid/ciu696openalex-snapshot

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

inferredcites →https://doi.org/10.1093/med/9780199609147.003.0027openalex-snapshot

Summary of product characteristics

inferredcites →https://doi.org/10.1111/hae.12533openalex-snapshot

Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey

inferredcites →https://doi.org/10.1128/aac.00051-16openalex-snapshot

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

inferredcites →https://doi.org/10.1128/aac.00324-12openalex-snapshot

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

inferredcites →https://doi.org/10.1128/aac.02494-12openalex-snapshot

Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

inferredcites →https://doi.org/10.1128/aac.02929-15openalex-snapshot

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle

inferredcites →https://doi.org/10.3851/imp3177openalex-snapshot

Pooled Analysis of HCV Genotype 1 Resistance-Associated Substitutions in NS5A, NS3 and NS5B pre- and Post-Treatment with 12 Weeks of Daclatasvir, Asunaprevir and Beclabuvir

inferredcites →https://doi.org/10.5604/01.3001.0010.7532openalex-snapshot

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection

inferredcites →https://doi.org/10.7326/m15-0785openalex-snapshot

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

inferredcites →https://doi.org/10.7326/m16-0816openalex-snapshot

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4613660openalex-extracted

Prevalence of Drug Resistance Associated Substitutions in Hepatitis C-Infected Patients Whose WHO-Recommended Direct Acting Agents for Initial Treatment and Retreatment Fails: A Systematic Review and Meta-Analysis

inferred← citeshttps://doi.org/10.1002/9781683670438.mcm0115openalex-snapshot

Mechanisms of Resistance to Antiviral Agents

inferred← citeshttps://doi.org/10.1002/9781683674849.mcm0115openalex-snapshot

Mechanisms of Resistance to Antiviral Agents

inferred← citeshttps://doi.org/10.1007/978-3-030-03757-4_2openalex-snapshot

Laboratory and Molecular Diagnosis of Hepatitis C and Resistance Testing

inferred← citeshttps://doi.org/10.1016/j.ijid.2020.03.061openalex-snapshot

NS5A resistance – associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey

inferred← citeshttps://doi.org/10.1016/j.jhep.2020.11.017openalex-snapshot

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

inferred← citeshttps://doi.org/10.1016/j.jhep.2021.03.004openalex-snapshot

Treatment failure with DAA therapy: Importance of resistance

inferred← citeshttps://doi.org/10.1016/j.jhep.2021.04.057openalex-snapshot

Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir

inferred← citeshttps://doi.org/10.1016/j.jhep.2022.08.016openalex-snapshot

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

inferred← citeshttps://doi.org/10.1038/s44259-025-00125-zopenalex-snapshot

Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals

inferred← citeshttps://doi.org/10.1093/cid/ciae431openalex-snapshot

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis

inferred← citeshttps://doi.org/10.1093/jac/dkaa091openalex-snapshot

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM

inferred← citeshttps://doi.org/10.1111/liv.15211openalex-snapshot

Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long‐term follow‐up study

inferred← citeshttps://doi.org/10.1128/aac.01269-19openalex-snapshot

Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

inferred← citeshttps://doi.org/10.1128/aac.01280-18openalex-snapshot

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A

inferred← citeshttps://doi.org/10.1155/2022/3556780openalex-snapshot

Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review

inferred← citeshttps://doi.org/10.18470/1992-1098-2024-1-4openalex-snapshot

Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region

inferred← citeshttps://doi.org/10.22625/2072-6732-2018-10-4-30-36openalex-snapshot

Drug resistant variants of hepatitis C virus genotype 1b in Russia: analysis of aminoacid substitutions in NS5a and core proteins

inferred← citeshttps://doi.org/10.22625/2072-6732-2020-12-1-104-110openalex-snapshot

Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V

inferred← citeshttps://doi.org/10.3390/biomedicines8040080openalex-snapshot

Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C

inferred← citeshttps://doi.org/10.3390/pathogens13080674openalex-snapshot

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

inferred← citeshttps://doi.org/10.3390/v11111004openalex-snapshot

Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports

inferred← citeshttps://doi.org/10.3390/v16081250openalex-snapshot

Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.